National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 72683 [2013-28851]
Download as PDF
<![CDATA[
72683
Federal Register / Vol. 78, No. 232 / Tuesday, December 3, 2013 / Notices
likely to begin and accelerates, often
leading to substance abuse disorder.
Notably, the peak period for the
manifestation of cannabis-use disorder
is age 18–19, and the past-yearprevalence for alcohol-use disorder is
age 20–22. The TLI is designed to
identify the propensity for these and
other substance abuse prior to
manifestation; as such, collecting data
from the high school age group (14–18
years old) is critical to identifying atrisk youths for the purposes of early
intervention. Thus, the TLI must be
tested with data collected from youth
populations, ages 14 to 18, comparable
to those in existing studies. Moreover,
the R&D team must provide
psychometric external validation for the
TLI through data collection from sets of
identical and fraternal twins.
Psychometric analyses are required to
show that the TLI performs according to
expectations. Accordingly, studies will
be performed on the collected
information to demonstrate i) construct,
ii) discriminative, iii) concurrent, and
iv) predictive validity.
OMB approval is requested for 2
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
3,083.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent: individuals and households
Number of
respondents
Parent of 14–17 year-old students: Consent Form .........................................
14–18 year-old students: School Survey (TLI) ................................................
14–18 year-old youths or their parents: Consent Form ..................................
14–18 year-old youths: Twins Survey (Demo/D&A) ........................................
14–18 year-old youths: Twins Survey (Dysregulation) ....................................
14–18 year-old youths: Twins Survey (TLI) ....................................................
5,000
........................
600
........................
........................
........................
Dated: November 20, 2013.
Glenda J. Conroy,
Executive Officer (OM Director), NIDA, NIH.
[FR Doc. 2013–28985 Filed 12–2–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
emcdonald on DSK67QTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke, Special
Emphasis Panel, Stroke Trials NetworkNDMC.
Date: December 18, 2013.
Time: 9:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
VerDate Mar<15>2010
18:56 Dec 02, 2013
Jkt 232001
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Natalia Strunnikova,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, NINDS, NIH, NSC, 6001 Executive
Blvd., Suite 3208, MSC 9529, Bethesda, MD
20892–9529, 301–402–0288,
Natalia.Strunnikova@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: November 26, 2013.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–28854 Filed 12–2–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
PO 00000
Frm 00058
Fmt 4703
Sfmt 9990
Average
burden per
response
(in hours)
Responses
per
respondent
1
1
1
1
1
1
Annual hour
burden
1/60
30/60
1/60
10/60
10/60
29/60
83
2,500
10
100
100
290
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, PAR13–228:
Biomarkers for Diabetes, Digestive, Kidney
and Urologic Diseases using Repository
Biosamples.
Date: February 20, 2014.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Najma Begum, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 749, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8894,
begumn@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: November 26, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–28851 Filed 12–2–13; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\03DEN1.SGM
03DEN1
]]>Agencies
[Federal Register Volume 78, Number 232 (Tuesday, December 3, 2013)]
[Notices]
[Page 72683]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-28851]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, PAR13-228: Biomarkers
for Diabetes, Digestive, Kidney and Urologic Diseases using
Repository Biosamples.
Date: February 20, 2014.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: Najma Begum, Ph.D., Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 749,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8894,
begumn@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: November 26, 2013.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-28851 Filed 12-2-13; 8:45 am]
BILLING CODE 4140-01-P
